Clinical Trial Update: Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating bemcentinib for myelodysplastic syndromes and related conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome
• Low-risk Myelodysplastic Syndrome

Drugs mentioned

• Bemcentinib (bemcentinib)

Snippet

Sponsor: GWT-TUD GmbH | Conditions: Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED